ArticleJournal of cutaneous pathology2026
Atypical Fibroxanthoma/Pleomorphic Dermal Sarcoma With Osseous Metaplasia: A Series of Three Cases.
Article in Journal of cutaneous pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) are rare mesenchymal tumors typically arising on sun-damaged skin of the head and neck in elderly patients. PDS is a more aggressive tumor but with similar demographics, cellular morphology, immunohistochemical features, and genetic findings. The histopathologic diversity and lack of specific immunohistochemical markers for these entities increase the risk of misdiagnosis. To our knowledge, osteoid matrix production has been noted previously in only one case of PDS. We present three additional cases of AFX/PDS with osseous metaplasia, all of which were from the head of elderly patients (91-93 years old). No case recurred or metastasized, thus underscoring the importance of distinguishing this entity from other primary or metastatic tumors with osseous differentiation or metaplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.